🚀 VC round data is live in beta, check it out!
Niagen Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Niagen Bioscience and similar public comparables like Grape King Bio, Medy-Tox, Zhejiang Shouxiangu, FitLife Brands and more.
Niagen Bioscience Overview
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Founded
2000
HQ
Employees
104
Website
Financials (LTM)
EV
$333M
Niagen Bioscience Financials
Niagen Bioscience reported last 12-month revenue of $133M and EBITDA of $23M.
In the same LTM period, Niagen Bioscience generated $86M in gross profit, $23M in EBITDA, and $18M in net income.
Revenue (LTM)
Niagen Bioscience P&L
In the most recent fiscal year, Niagen Bioscience reported revenue of $129M and EBITDA of $21M.
Niagen Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $133M | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $86M | XXX | $83M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $23M | XXX | $21M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $18M | XXX | $17M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Niagen Bioscience Stock Performance
Niagen Bioscience has current market cap of $394M, and enterprise value of $333M.
Market Cap Evolution
Niagen Bioscience's stock price is $4.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $333M | $394M | 0.0% | XXX | XXX | XXX | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNiagen Bioscience Valuation Multiples
Niagen Bioscience trades at 2.5x EV/Revenue multiple, and 14.6x EV/EBITDA.
EV / Revenue (LTM)
Niagen Bioscience Financial Valuation Multiples
As of March 21, 2026, Niagen Bioscience has market cap of $394M and EV of $333M.
Equity research analysts estimate Niagen Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Niagen Bioscience has a P/E ratio of 21.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $394M | XXX | $394M | XXX | XXX | XXX |
| EV (current) | $333M | XXX | $333M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 14.6x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 20.1x | XXX | 20.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 22.7x | XXX | XXX | XXX |
| EV/FCF | 19.3x | XXX | 25.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Niagen Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Niagen Bioscience Margins & Growth Rates
Niagen Bioscience's revenue in the last 12 month grew by 15%.
Niagen Bioscience's revenue per employee in the last FY averaged $1.3M.
Niagen Bioscience's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Niagen Bioscience's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Niagen Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | 21% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Niagen Bioscience Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Grape King Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| FitLife Brands | XXX | XXX | XXX | XXX | XXX | XXX |
| Venture Life Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Niagen Bioscience M&A Activity
Niagen Bioscience acquired XXX companies to date.
Last acquisition by Niagen Bioscience was on XXXXXXXX, XXXXX. Niagen Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Niagen Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNiagen Bioscience Investment Activity
Niagen Bioscience invested in XXX companies to date.
Niagen Bioscience made its latest investment on XXXXXXXX, XXXXX. Niagen Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Niagen Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Niagen Bioscience
| When was Niagen Bioscience founded? | Niagen Bioscience was founded in 2000. |
| Where is Niagen Bioscience headquartered? | Niagen Bioscience is headquartered in United States. |
| How many employees does Niagen Bioscience have? | As of today, Niagen Bioscience has over 104 employees. |
| Who is the CEO of Niagen Bioscience? | Niagen Bioscience's CEO is Robert N. Fried. |
| Is Niagen Bioscience publicly listed? | Yes, Niagen Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Niagen Bioscience? | Niagen Bioscience trades under NAGE ticker. |
| When did Niagen Bioscience go public? | Niagen Bioscience went public in 2008. |
| Who are competitors of Niagen Bioscience? | Niagen Bioscience main competitors are Grape King Bio, Medy-Tox, Zhejiang Shouxiangu, FitLife Brands. |
| What is the current market cap of Niagen Bioscience? | Niagen Bioscience's current market cap is $394M. |
| What is the current revenue of Niagen Bioscience? | Niagen Bioscience's last 12 months revenue is $133M. |
| What is the current revenue growth of Niagen Bioscience? | Niagen Bioscience revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Niagen Bioscience? | Current revenue multiple of Niagen Bioscience is 2.5x. |
| Is Niagen Bioscience profitable? | Yes, Niagen Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Niagen Bioscience? | Niagen Bioscience's last 12 months EBITDA is $23M. |
| What is Niagen Bioscience's EBITDA margin? | Niagen Bioscience's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Niagen Bioscience? | Current EBITDA multiple of Niagen Bioscience is 14.6x. |
| What is the current FCF of Niagen Bioscience? | Niagen Bioscience's last 12 months FCF is $17M. |
| What is Niagen Bioscience's FCF margin? | Niagen Bioscience's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Niagen Bioscience? | Current FCF multiple of Niagen Bioscience is 19.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.